DNMT1 | DNA (cytosine-5-)-methyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
DPEP1 | Dipeptidase 1 (renal) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
DPP4 | Dipeptidyl-peptidase 4 | CD markers Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
DRD1 | Dopamine receptor D1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
DRD2 | Dopamine receptor D2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
DRD3 | Dopamine receptor D3 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Not detected |
DRD4 | Dopamine receptor D4 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Not detected |
DRD5 | Dopamine receptor D5 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
EDNRA | Endothelin receptor type A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EDNRB | Endothelin receptor type B | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EGF | Epidermal growth factor | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Group enriched |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ELANE | Elastase, neutrophil expressed | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
EPHA2 | EPH receptor A2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
EPOR | Erythropoietin receptor | Cancer-related genes Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ERBB4 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
ESR1 | Estrogen receptor 1 | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
ESR2 | Estrogen receptor 2 (ER beta) | Cancer-related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
ESRRG | Estrogen-related receptor gamma | FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
F10 | Coagulation factor X | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
F11 | Coagulation factor XI | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
F2 | Coagulation factor II (thrombin) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
F5 | Coagulation factor V (proaccelerin, labile factor) | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
F7 | Coagulation factor VII (serum prothrombin conversion accelerator) | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
F8 | Coagulation factor VIII, procoagulant component | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
F9 | Coagulation factor IX | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
FADS1 | Fatty acid desaturase 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FADS2 | Fatty acid desaturase 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FASN | Fatty acid synthase | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
FCER1A | Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
FCER1G | Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
FCGR1A | Fc fragment of IgG, high affinity Ia, receptor (CD64) | CD markers FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
FCGR1B | Fc fragment of IgG, high affinity Ib, receptor (CD64) | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FCGR2A | Fc fragment of IgG, low affinity IIa, receptor (CD32) | CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
FCGR2B | Fc fragment of IgG, low affinity IIb, receptor (CD32) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
FCGR3A | Fc fragment of IgG, low affinity IIIa, receptor (CD16a) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
FCGR3B | Fc fragment of IgG, low affinity IIIb, receptor (CD16b) | CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
FDPS | Farnesyl diphosphate synthase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
FFAR1 | Free fatty acid receptor 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
FGA | Fibrinogen alpha chain | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
FGF1 | Fibroblast growth factor 1 (acidic) | Cancer-related genes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Group enriched |
FGF2 | Fibroblast growth factor 2 (basic) | Cancer-related genes Candidate cardiovascular disease genes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Mixed |
FGFR1 | Fibroblast growth factor receptor 1 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FKBP1A | FK506 binding protein 1A, 12kDa | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FLT1 | Fms-related tyrosine kinase 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |
FLT3 | Fms-related tyrosine kinase 3 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
FLT4 | Fms-related tyrosine kinase 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FN1 | Fibronectin 1 | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |